Allos Completes Enrollment in Phase II Lymphoma Study
Posted on: Wednesday, 23 April 2008, 12:00 CDT
Allos Therapeutics has completed patient enrollment in Propel, the company's pivotal Phase II trial of PDX in patients with relapsed or refractory peripheral T-cell lymphoma.
Propel is a pivotal Phase II, international, multi-center, open-label, single-arm study that enrolled patients with relapsed or refractory PTCL who progressed after at least one prior treatment. Patients will receive 30 mg/m2 of PDX once every week for six weeks followed by one week of rest per cycle of treatment. The treatment regimen also includes vitamin B12 and folic acid supplementation.
The primary endpoint of the study is objective response rate (complete and partial response). Secondary endpoints include duration of response, progression-free survival and overall survival.
Pablo Cagnoni, chief medical officer of Allos, said: "We believe that PDX has the potential to offer a new treatment option for patients with this challenging disease and look forward to reporting top line results of the trial later this year."
Source: Datamonitor
Related Articles
- Repligen Announces Completion of Patient Treatment in Phase 3 Clinical Trial of RG1068 in MRI Imaging of the Pancreas
- Oculus Completes Patient Treatment in Phase II Diabetic Foot Ulcer Trial
- Oculus Innovative Sciences Completes Patient Treatment and Follow-Up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
- Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
- USNS Comfort Conducts 55,465 Patient Treatments in First Month
- Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
- Viventia Initiates Patient Treatment in Bladder Cancer Trial
- Work Starts on ASH's List of Repairs: Recent Analysis Showed Breakdowns in Patient Treatment
- New Blood Test Helps Personalize Patients' Treatment
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
 |
 |
User Comments (0)
RSS Feeds